Literature DB >> 16459334

Transport of the IgE receptor alpha-chain is controlled by a multicomponent intracellular retention signal.

David M Cauvi1, Xufang Tian, Katharina von Loehneysen, Michael W Robertson.   

Abstract

The human high affinity IgE receptor (FcepsilonRI) is a central component of the allergic response and is expressed as either a trimeric alphagamma2 or tetrameric alphabetagamma2 complex. It has been previously described that the cytoplasmic domain (CD) of the alpha-chain carries a dilysine motif at positions -3/-7 from the C terminus that functions in intracellular retention prior to assembly with other FcepsilonRI subunits. In this report we have further explored the role of the -3/-7 dilysine signal in controlling steady-state alpha-chain transport by mutational analysis and found little surface expression of a -3/-7 dialanine alpha-chain mutant but significant Golgi localization. We compared the transport properties of a series of alpha-chain cytoplasmic domain truncation mutants and observed that truncation mutants lacking 23 or more C-terminal residues showed a dramatic increase in steady-state transport suggesting a role for the membrane-proximal CD sequence in alpha-chain retention. By performing alanine-scanning mutagenesis we identified a dilysine sequence (Lys(212)-Lys(216)) proximal to the transmembrane domain (TMD) that is important for both alpha-chain cell-surface expression and intracellular stability. Furthermore, co-mutation of the Lys(212)-Lys(216) residues with the -3/-7 dilysine signal produced a dramatic increase in alpha-chain surface expression that was further increased by co-mutation of the lone charged residue (Asp(192)) in the TMD thereby defining three regions that function to regulate alpha-chain transport and in a highly synergistic manner.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16459334     DOI: 10.1074/jbc.M510751200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Transmembrane features governing Fc receptor CD16A assembly with CD16A signaling adaptor molecules.

Authors:  Alfonso Blázquez-Moreno; Soohyung Park; Wonpil Im; Melissa J Call; Matthew E Call; Hugh T Reyburn
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-26       Impact factor: 11.205

2.  The signal peptide of the IgE receptor alpha-chain prevents surface expression of an immunoreceptor tyrosine-based activation motif-free receptor pool.

Authors:  Barbara Platzer; Edda Fiebiger
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

3.  The first transmembrane region of the beta-chain stabilizes the tetrameric Fc epsilon RI complex.

Authors:  Theresa E Singleton; Barbara Platzer; Eleonora Dehlink; Edda Fiebiger
Journal:  Mol Immunol       Date:  2009-04-29       Impact factor: 4.407

Review 4.  Immunoglobulin E receptor signaling and asthma.

Authors:  Lawren C Wu
Journal:  J Biol Chem       Date:  2011-07-28       Impact factor: 5.157

Review 5.  Anchors aweigh: protein localization and transport mediated by transmembrane domains.

Authors:  Pierre Cosson; Jackie Perrin; Juan S Bonifacino
Journal:  Trends Cell Biol       Date:  2013-06-24       Impact factor: 20.808

6.  Characterization of human FcεRIα chain expression and gene copy number in humanized rat basophilic leukaemia (RBL) reporter cell lines.

Authors:  Eman Ali Ali; Marina Kalli; Daniel Wan; Ryosuke Nakamura; David Onion; Daniel G W Alanine; Marcos J C Alcocer; Franco H Falcone
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

7.  ERAD of proteins containing aberrant transmembrane domains requires ubiquitylation of cytoplasmic lysine residues.

Authors:  Kit Briant; Yee-Hui Koay; Yuka Otsuka; Eileithyia Swanton
Journal:  J Cell Sci       Date:  2015-10-07       Impact factor: 5.285

Review 8.  Two Sides of the Coin: Mast Cells as a Key Regulator of Allergy and Acute/Chronic Inflammation.

Authors:  Zhongwei Zhang; Yosuke Kurashima
Journal:  Cells       Date:  2021-06-28       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.